Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06561308 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 1, 2026 → Dec 1, 2027
See other at-risk trials from Women's Hospital School Of Medicine Zhejiang University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 1, 2026 to Dec 1, 2027
    • Study completion pushed from Dec 1, 2031 to Dec 1, 2032
    • Secondary endpoints: details revised at 1 of 5 entries
    v4
  2. Primary completion date: Dec 1, 2026 to Dec 1, 2027v3 Show 5 more changesShow less
    • Study completion date: Dec 1, 2031 to Dec 1, 2032
    • Secondary endpoints: details revised at 2 of 5 entries
    • Study description shortened, about 11 words
    • Collaborators: 11 to 12
    • Eligibility criteria expanded, about 1 word
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 8 more changesShow less
    • Primary completion date: Sep 1, 2029 to Dec 1, 2026
    • Start date changed from estimate of Sep 1, 2024 to Sep 1, 2025
    • Study completion date: Dec 1, 2029 to Dec 1, 2031
    • Interventions: Carboplatin (Drug), Paclitaxel (Drug), Pucotenlimab (Drug), Surgery (Procedure) to Camrelizumab (Drug), Carboplatin (Drug), Paclitaxel (Drug), Surgery (Procedure)
    • Eligibility criteria revised
    • Site details revised
    • Study description shortened, about 4 words
    • Study title expanded, about 1 word
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Exploring the therapeutic effect of neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab on advanced stage III-IV endometrial cancer
Trial Details
NCT Number NCT06561308
Lead Sponsor Women's Hospital School Of Medicine Zhejiang University
Collaborators: Xiangya Hospital of Central South University, Tongji Hospital, Qilu Hospital of Shandong University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Henan Provincial People's Hospital, Hunan Cancer Hospital, Zhejiang Cancer Hospital, First Affiliated Hospital of Wenzhou Medical University, Ningbo No. 1 Hospital, The First Affiliated Hospital of Zhengzhou University, Tianjin Medical University General Hospital
Conditions
(from sponsor)		 Endometrioid Endometrial Cancer
Enrollment 39 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov